biotech
Antisoma Recruits Patients for AS1411 Extended Phase I Trials
Filed in archive Drugs, Vaccines and Therapeutics by ruth on September 6, 2005
BlogPicture

In a Phase I Clinical Trial involving 17 patients with various types of cancer, Antisoma's drug candidate AS1411 showed promising anti-renal cancer activity. Antisoma was able to secure a U.S. orphan drug status for AS1411 in renal cancer, and is now recruiting 40 patients with renal and non-small cell lung cancers to participate in an extended study.
AS1411 is an aptamer, an oligonucleotide that can fold into a stable, three-dimensional structure capable of interacting with a particular target protein. AS1411 binds to the protein nucleolin, which is found on the surface of cancer cells. It is then internalised and has been shown to kill cancer cells in a range of models.


The reopened study is taking place at centres in the USA, led by the Brown Cancer Center, Louisville, Kentucky.



Permalink: Antisoma Recruits Patients for AS1411 Extended Phase I Trials
Tags: cancer  renalcancer  biotech  as1411  phase  phase+trials  antisoma+recruits  as1411+extended 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/9004
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Antisoma Recruits Patients for AS1411 Extended Phase I Trials:

  • Currently 8.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 8.00 out of 4 vote(s) cast.
 
Subscribe
Share It
Popular posts from our other blogs:
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!